B
Ben A. C. Dijkmans
Researcher at VU University Medical Center
Publications - 78
Citations - 8290
Ben A. C. Dijkmans is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 44, co-authored 78 publications receiving 7881 citations. Previous affiliations of Ben A. C. Dijkmans include University of Amsterdam.
Papers
More filters
Journal ArticleDOI
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Yvonne P M Goekoop-Ruiterman,J.K. de Vries-Bouwstra,Cornelia F Allaart,D. Van Zeben,Pit J S M Kerstens,Johanna M. W. Hazes,A. H. Zwinderman,H. K. Ronday,K.H. Han,M. L. Westedt,Andreas H. Gerards,J.H.L.M. van Groenendael,Willem F. Lems,M V van Krugten,Ferdinand C. Breedveld,Ben A. C. Dijkmans +15 more
TL;DR: In patients with early RA, initial combination therapy including either prednisone or infliximab resulted in earlier functional improvement and less radiographic damage after 1 year than did sequential monotherapy or step-up combination therapy.
Journal ArticleDOI
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
Maarten Boers,A. C. Verhoeven,Harry M Markusse,Mart A F J van de Laar,Rene Westhovens,J Christiaan van Denderen,Derkjen van Zeben,Ben A. C. Dijkmans,André Peeters,P. Jacobs,Hans R van den Brink,Hubert Ja Schouten,Désirée van der Heijde,Annelies Boonen,Sjef van der Linden +14 more
TL;DR: This combined-therapy regimen offers additional disease control over and above that of sulphasalazine alone that persists for up to a year after corticosteroids are stopped.
Journal ArticleDOI
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
Désirée van der Heijde,Ben A. C. Dijkmans,Piet Geusens,Joachim Sieper,Kimberly Dewoody,Paul Williamson,Jürgen Braun +6 more
TL;DR: Clinical benefit was observed in patients receiving infliximab as early as week 2 and was maintained over the 24-week study period, and well tolerated and effective in a large cohort of patients with AS during a 24- week study period.
Journal ArticleDOI
Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission.
Esmeralda T. H. Molenaar,Alexandre E. Voskuyl,Huib J. Dinant,P. Dick Bezemer,Maarten Boers,Ben A. C. Dijkmans +5 more
TL;DR: Although rare, clinically relevant progression of joint damage does occur in patients with RA in prolonged remission, and the need for markers that predict progression during periods of low disease activity and for drugs that prevent damage that is independent of disease activity is suggested.
Journal ArticleDOI
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study
Vokko P van Halm,Michael T. Nurmohamed,Jos W. R. Twisk,Ben A. C. Dijkmans,Alexandre E. Voskuyl +4 more
TL;DR: It is hypothesize that DMARD use, in particular MTX use, results in powerful suppression of inflammation, thereby reducing the development of atherosclerosis and subsequently clinically overt CVD.